首页期刊导航|国际免疫学杂志
期刊信息/Journal information
国际免疫学杂志
国际免疫学杂志

李殿俊

双月刊

1673-4394

guojimianyi@126.com

0451-86669596

150081

黑龙江省哈尔滨市南岗区保健路157号

国际免疫学杂志/Journal International Journal of Immunology北大核心CSTPCD
查看更多>>1978年创刊，中华人民共和国卫生部主管，中华医学会、哈尔滨医科大学主办。本刊原名《国外医学》免疫学分册，公开发行的国家级学术期刊。期刊适合于从事免疫学以及相关学科、交叉学科的科研、教学和广大的临床医务工作者参考和交流。
正式出版
收录年代

    PI3K/Akt信号通路在狼疮肾炎发病中的研究进展

    程芷洛孟祥文贾晓益张敏...
    178-182页
    查看更多>>摘要：狼疮肾炎(lupus nephritis, LN)是系统性红斑狼疮(systemic lupus erythematosus, SLE)中常见的并发症，其中10%～20%的LN患者会在确诊后5年内发展到终末期肾病，进而危及生命。磷脂酰肌醇3激酶(phosphatidylinositol 3 kinase, PI3K)/蛋白激酶B(protein kinase B, Akt)(简称PI3K/Akt信号通路)是细胞周期过程中重要的信号通路之一。近几年显示PI3K/Akt信号通路与LN的发生发展有关，文章总结了PI3K/Akt信号通路在LN中的机制研究和相关抑制剂，以期为LN的治疗靶点提供新的思路。 Lupus nephritis(LN) is a common complication of systemic lupus erythematosus(SLE), with 10%~20% of patients with LN developing the life-threatening end-stage renal disease within 5 years of diagnosis.Phosphatidylinositol 3 kinase(PI3K)/protein kinase B(Akt)(PI3K/Akt signaling pathway) is one of the important signaling pathways during the cell cycle.In recent years, it has been shown that PI3K/Akt signaling pathway is associated with the development of LN.The mechanistic studies of the PI3K/Akt signaling pathway in LN and related inhibitors, with a view to providing new ideas for therapeutic targets in LN were summarized.

    狼疮肾炎PI3K/Akt信号通路抑制剂

      原文链接:
    • 万方数据

    氧化应激在系统性红斑狼疮发病机制中的作用

    陈琴夏育民
    183-189页
    查看更多>>摘要：系统性红斑狼疮(systemic lupus erythematosus，SLE)是一种多系统受累的自身免疫性疾病，通常认为遗传与免疫因素主要参与其发病。近年研究发现，氧化应激可导致SLE患者辅助性T细胞和调节性T细胞分化失衡以及线粒体功能障碍，通过对脂质、蛋白质和核酸等生物大分子进行氧化修饰，触发自身免疫，导致免疫复合物沉积并损伤靶器官。氧化应激还能降低DNA甲基化水平从而使相关基因过表达，但具体机制尚不清楚。抑制氧化应激可作为防治SLE的有效方法，延缓病情发展。文章将着重讨论氧化应激如何参与SLE的发生发展，以及针对氧化应激的抗氧化治疗方法，为SLE患者的临床治疗提供新的思路。 Systemic lupus erythematosus (SLE) is a kind of autoimmunity disease with multiple systems involved. It is generally believed that genetic and immune factors are involved in the pathogenesis of SLE. In recent years, it was found that oxidative stress leads to the imbalance of helper T cell and regulatory T cell differentiation and mitochondrial dysfunction in SLE patients. Oxidative modification of lipids and proteins may trigger autoimmunity and lead to immune complex deposition and damage to target organs. Oxidative stress also reduces the level of DNA methylation and promotes the expression of related genes, but the exact mechanism is still unclear. The oxidative stress pathway may be used as a new target for the treatment of SLE patients, and alleviate the disease progression. The review will focus on how oxidative stress is involved in the pathogenesis of SLE and the antioxidant therapies, so as to provide new ideas for the clinical treatment of patients with SLE.

    红斑狼疮氧化应激靶器官损害抗氧化治疗

      原文链接:
    • 万方数据

    miRNA在糖尿病性视网膜病变中的最新研究进展

    王昌琴吕洋
    190-195页
    查看更多>>摘要：糖尿病视网膜病变(diabetic retinopathy，DR)是糖尿病最常见、最典型的微血管并发症之一，也是我国成人失明或严重视力丧失的主要原因。目前关于DR的治疗主要包括药物治疗、激光治疗以及手术治疗，但这些治疗多为侵入性、破坏性的治疗，且不良反应多，因此寻找新的治疗靶点成为防治DR的热点。微小RNA(microRAN，miRNA)是理想的生物标志物，在细胞凋亡、炎症、氧化应激、病理性新生血管的形成中起到重要的调控作用，有望成为治疗DR的生物学标志物，文章总结了miRNA在DR治疗中的最新研究进展，为DR的临床防治提供新的思路。 Diabetic retinopathy (DR) is one of the most common and typical microvascular complications of diabetes mellitus, and it is also the main cause of blindness or severe visual loss in adults in China. At present, the treatment of DR mainly includes drug therapy, laser therapy and surgical treatment, but most of these treatments are invasive and destructive, and have many adverse reactions. Therefore, finding new therapeutic targets has become a hot spot in the prevention and treatment of DR. MicroRNA(miRNA) is an ideal biomarker, which plays an important regulatory role in apoptosis, inflammation, oxidative stress and pathological neovascularization, and is expected to become a biomarker for the treatment of DR. This article summarizes the latest research progress of miRNA in the treatment of DR, and provides new ideas for the clinical prevention and treatment of DR.

    糖尿病性视网膜病变miRNA慢性炎症氧化应激免疫反应靶向治疗

      原文链接:
    • 万方数据

    口腔微生物与类风湿关节炎的研究进展

    荀逸萌王秦张泽锦范婷婷...
    196-200页
    查看更多>>摘要：类风湿关节炎(rheumatoid arthritis，RA)是目前致残率较高的一种疾病。口腔微生物作为人类第二大微生物组已发现与免疫系统有着密切关系。共生微生物在维持体内平衡和健康方面发挥着核心作用，不仅通过阻断微生物活动，而且通过专门机制增强人类免疫系统。有研究指出RA患者的口腔微生物群落与健康人相比存在显著失调，这种生态失调可通过RA的治疗而恢复，且恢复程度与患者对治疗的反应密切相关。明确口腔微生物在RA发生发展中的作用，能为其治疗提供新的方向。 Rheumatoid arthritis(RA) is currently a disease with a high disability rate. The oral microbiome, the second largest microbiome in humans, has been found to be closely related to the immune system. Symbiotic microorganisms play a core role in maintaining balance and health within the body, not only by blocking microbial activity, but also by enhancing the human immune system through specialized mechanisms.Studies have pointed out that the oral microflora of patients with rheumatoid arthritis has a significant imbalance compared with healthy people, and this dysbiosis can be recovered by the treatment of rheumatoid arthritis, and the degree of recovery is closely related to the patient's response to treatment. Clarifying the role of oral microorganisms in the occurrence and development of rheumatoid arthritis can provide a new direction for its treatment.

    类风湿关节炎微生物口腔

      原文链接:
    • 万方数据

    间充质干细胞外泌体在皮肤组织修复与再生中的机制及临床应用研究进展

    梁俊琴胡凤侠康晓静
    201-206页
    查看更多>>摘要：间充质干细胞是起源于中胚层的非造血干细胞，可在体外增殖并具有自我更新、多向分化潜能和免疫调节功能。间充质干细胞来源的外泌体是细胞间传递信号的重要分子介质，可运输蛋白质、代谢物和各种核酸，具有与间充质干细胞相似的生物学功能，因其更稳定且具有较低的免疫原性，在抗衰老、皮肤伤口愈合及部分皮肤疾病中发挥重要作用，但具体机制尚不明确。文章将从间充质干细胞外泌体在皮肤组织修复与再生中的机制研究与临床应用现状进行综述。 Mesenchymal stem cells are non-hematopoietic stem cells originating from mesoderm, which can proliferate in vitro and have the potential of self-renewal, multidirectional differentiation and immunomodulatory functions. Exosomes derived from mesenchymal stem cells are important molecular mediators for signaling between cells, and can transport proteins, metabolites and various nucleic acids. They have similar biological functions as mesenchymal stem cells. Due to their greater stability and lower immunogenicity, they play an important role in anti-aging, skin wound healing and some skin diseases, but the specific mechanism remains unclear. Therefore, this article reviews the mechanism research and clinical application of mesenchymal stem cell exosomes in skin tissue repair and regeneration.

    间充质干细胞外泌体组织修复再生皮肤

      原文链接:
    • 万方数据

    外泌体miRNAs应用于卵巢癌诊断的研究进展

    李东伟王波陈悦彤丁海涛...
    207-212页
    查看更多>>摘要：卵巢癌是导致妇女死亡的主要恶性肿瘤之一。其早期诊断困难，无任何标准的筛查方法，且治疗效果差，容易发生耐化疗情况，患者的存活率不高。因此，明确卵巢癌发生发展机制以及探索新的早期诊断标志物对于临床诊疗以及监测预后尤为重要。血清糖类抗原125(carbohydrate antigen 125，CA125)、人附睾蛋白4(human epididymis protein, HE4)等肿瘤标志物的应用对于卵巢癌的诊断及判断肿瘤的治疗效果有重要意义，但这些标志物的敏感性和特异性都无法满足早期诊断的要求，因此在卵巢癌的早期筛查中仍具有一定的局限性。随着近几年对外泌体微小RNA(micro RNA，miRNA)的研究，发现miRNAs在肿瘤发展、转移和侵袭等进程中发挥了重要作用，且分布广泛，具有良好的稳定性，是卵巢癌潜在的生物标志物。文章对外泌体miRNAs在卵巢癌早期诊断中的应用进展的最新研究进行综述。 Ovarian cancer is one of the leading malignancies that cause death in women.Its early diagnosis is difficult, there is no standard screening method, and the treatment effect does not work well, chemotherapy resistance is easy to occur, and the survival rate of patients is not high.Therefore, it is of utmost significance to elucidate the etiology and progression of ovarian cancer, as well as investigate novel biomarkers for early detection, clinical diagnosis, treatment, and prognostic evaluation.The application of tumor markers such as serum carbohydrate antigen 125(CA125) and human epididymis protein 4(HE4) is of great significance for the diagnosis of ovarian cancer and the diagnosis of tumor treatment effect, but the sensitivity and specificity of these markers cannot meet the requirements of early diagnosis, so they still have certain limitations in the early screening of ovarian cancer.With the research on exosomal microRNA(miRNA) in recent years, it has been found that miRNAs play an important role in the process of tumor development, metastasis and invasion, and are widely distributed and have good stability, which is a potential biomarker for ovarian cancer.The latest research progress on the application of exosomal miRNAs in the early diagnosis of ovarian cancer was reviewed.

    外泌体微小RNA卵巢癌早期诊断

      原文链接:
    • 万方数据

    CD137-CD137L与1型糖尿病的相关性研究进展

    李世兰薛君力
    213-217页
    查看更多>>摘要：1型糖尿病(type 1 diabetes mellitus, T1DM)是一种多因素免疫介导的与自身免疫密切相关的疾病，其发病机制尚不完全明确，近年来发现，T细胞及其细胞亚群的活化与T1DM发生密切相关，而CD137-CD137L信号通路是T细胞活化的重要协调分子。文章就CD137-CD137L共刺激通路的相互作用及在T1DM发生、发展及免疫治疗中的影响进行综述。 Type 1 diabetes (T1DM) is a multifactorial immune mediated disease closely related to autoimmunity, and its pathogenesis is not completely clear. In recent years, it has been found that the activation of T cells and their subsets is closely related to the occurrence of T1DM, and CD137-CD137L signaling pathway is an important co modulator of T cell activation. The interaction of CD137-CD137L costimulatory pathway and its influence on the occurrence, development and immunotherapy in T1DM were reviewed.

    CD137-CD137L免疫治疗1型糖尿病

      原文链接:
    • 万方数据

    肿瘤引流淋巴结中PD-L1的表达及作用研究进展

    闫智恒齐秀英张雅芳
    218-222页
    查看更多>>摘要：肿瘤引流淋巴结(tumor draining lymph node, TDLN)对肿瘤免疫至关重要，肿瘤细胞产生的一系列细胞因子通过淋巴管在肿瘤转移之前改变了淋巴结的免疫微环境和淋巴结基质，破坏了TDLN的免疫功能，为肿瘤细胞的转移创造条件。作为抗肿瘤免疫的重要蛋白，程序性死亡配体1(programmed death ligand 1, PD-L1)在TDLN中的表达水平和表达位置发生了变化。与此同时，TDLN中PD-L1在肿瘤免疫治疗中起到十分重要的作用。文章介绍了TDLN免疫微环境和淋巴结基质的变化，阐述了PD-L1在TDLN中的作用、分布以及临床治疗中的机制和作用。 Tumor draining lymph node (TDLN) is crucial for tumor immunity. A series of cytokines produced by tumor cells change the immune microenvironment and lymph node matrix through lymph vessels before tumor metastasis, destroying the immune function of TDLN. Creating conditions for tumor cells to metastasize. As an important protein in anti-tumor immunity, the expression level and position of programmed death ligand 1 (PD-L1) in TDLN are changed. At the same time, the PD-L1 of TDLN plays a very important role in tumor immunotherapy. This paper introduces the changes of immune microenvironment and lymph node stroma of TDLN, and expounds the role, distribution and mechanism of clinical treatment of PD-L1 in TDLN.

    程序性死亡配体1肿瘤引流淋巴结免疫微环境

      原文链接:
    • 万方数据

    Blinatumomab治疗儿童复发难治性急性B淋巴细胞白血病2例

    李亚珍汉英吴涛石亚军...
    223-225页
    查看更多>>摘要：急性淋巴细胞白血病(acute lymphoblastic leukmia，ALL)是一种发生在B细胞或T细胞系的未成熟淋巴细胞的肿瘤性疾病，其中B细胞亚型最常见。ALL约占所有儿童癌症的26%，成人发病率相对较低[1]。大约90%的儿童患者通过初始诱导化疗能达到完全缓解(complete response，CR)，诱导化疗药物通常包括柔红霉素、长春新碱、皮质类固醇和门冬酰胺酶。虽然儿童ALL患者的5年总生存率(overall survival，OS)为85%，然而传统化疗方案对于复发/难治性(relapsed/refractory，R/R)急性淋巴细胞白血病(R/R B-ALL)患儿的治疗效果较差，OS更差[2]，导致很多患儿死于疾病进展。传统上，挽救性治疗的选择有限，主要包括更标准的附加细胞毒性的化疗。近期多项临床研究证实Blinatumomab(贝林妥欧单抗)在R/R B-ALL中有较好的疗效，且患者耐受性良好，目前已被美国食品药品监督管理局(Food and Drug Administration，FDA)批准用于R/R和微小残留病灶(minimal residual disease，MRD)阳性的B-ALL治疗[3]。现报道解放军联勤保障部队第九四○医院血液科于2021至2022年接受Blinatumomab治疗的2例R/R B-ALL患儿的诊疗及缓解情况并进行相关文献复习。
      原文链接:
    • 万方数据

    脑膜瘤放疗后继发自身免疫性癫痫1例

    王海霞左志刚马天宇刘秀娟...
    226-228页
    查看更多>>摘要：患者因体检发现脑膜瘤，于北京"天坛医院"行脑膜瘤近全切除术，术后行辅助性放射治疗，后继发自身免疫相关性癫痫，表现为难治性癫痫，需多种抗癫痫药物及激素联合丙种球蛋白治疗，患者好转出院，现报道如下(伦理学审批文号：2023LW005)。

    脑膜瘤放疗自身免疫相关性癫痫难治性癫痫

      原文链接:
    • 万方数据